SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

African American men see biggest survival gain from healthier lifestyles post prostate cancer diagnosis

2.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

NIH research cuts leave cancer patient facing hard choice

5.

The Risk of Major Mortality is Associated with the Start of Opioids in Dementia.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot